Ocugen Leaders to Highlight Gene Therapy Progress for Inherited Retinal Diseases at Biotechnology Conferences

Ocugen Leaders to Highlight Gene Therapy Progress for Inherited Retinal Diseases at Biotechnology Conferences

Malvern, PA – Ocugen, Inc., a biotechnology company focused on gene therapies for blinding diseases, is set to make presentations at key biotechnology conferences in Puerto Rico and Italy. These events offer an important platform for the company to share updates on its innovative work, particularly its gene-agnostic modifier gene therapy platform, which is highly relevant to the inherited retinal disease (IRD) community.

For patients and families living with IRDs, these presentations represent opportunities to learn about the progress of potential new treatments. Ocugen's focus on gene-agnostic therapies is particularly significant, as these treatments aim to address the underlying mechanisms of retinal degeneration regardless of the specific genetic mutation causing the disease. This approach could potentially benefit a broader range of individuals within the IRD community.

Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen, will present at Oppenheimer's 3rd Annual Innovation on the Island Biotech Summit in Rio Grande, Puerto Rico, on April 28, 2026, at 8:20 a.m. AST. Abhi Gupta, MBA, Executive Vice President, will present at the Cell & Gene Meeting on the Mediterranean in Rome, Italy, on April 28, 2026, at 4:30 p.m. CEST. Both leaders will discuss the company's modifier gene therapy platform.

A key highlight of these presentations will be the discussion of Ocugen's lead product, OCU400. This gene-agnostic modifier gene therapy is currently in Phase 3 clinical development for retinitis pigmentosa (RP). The company has completed enrollment for its Phase 3 clinical trial for OCU400, a significant milestone. OCU400 is based on the NR2E3 gene, which helps regulate retinal functions, and aims to restore balance in affected retinal cellular networks.

Ocugen has also reported positive early results for OCU410ST, a modifier gene therapy in development for Stargardt disease, and recently completed dosing in its Phase 2/3 trial for this candidate. The company's pipeline also includes OCU410 for geographic atrophy.

These presentations underscore Ocugen's commitment to advancing novel treatments for inherited retinal diseases and other blinding conditions. The company anticipates a Biologics License Application (BLA) submission for OCU400 later this year, which could bring it closer to market availability. The ongoing progress in clinical trials and the engagement at these conferences provide a hopeful outlook for the future of IRD treatments.